Assessment of Quality of Life in Children With Pulmonary Hypertension Using Parent and Self-report Questionnaires.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Nov 2022
Historique:
pubmed: 19 11 2022
medline: 21 12 2022
entrez: 18 11 2022
Statut: ppublish

Résumé

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevation of pulmonary vascular resistance and right ventricular failure. By using advanced therapies to reduce mortality, clinicians focus on improving functional status and quality of life (QOL). The aim of our study was to assess health-related QOL of pediatric patients with PAH. Parents of all children (aged 2-18 years) and patients aged 5-18 years with an appropriate level of intellectual development completed general and cardiac-specific validated surveys (Pediatric Quality of Life Inventory 4.0 and Pediatric Quality of Life Inventory 3.0, respectively). Demographic and clinical information was collected to grade disease severity. Twenty-five children were enrolled, yielding 25 parent reports and 15 patient self-reports. The PAH group had significantly lower scores than healthy children in all domains. Patients with World Health Organization Functional Class I had significantly higher parent proxy scores in School Functioning (P = .029) and in Heart Problems and Symptoms domain (P = .014) Patients with tricuspid annular plane systolic excursion below -2 z score showed impairment in each parent proxy general domain and in the Cognitive Problems score of the Cardiac module (P = .006). In conclusion the QOL of patients with PAH was impaired in every domain compared with healthy children. Patients with reduced right ventricle systolic function showed significantly lower QOL in all core domains. These results point to the need for psychosocial rehabilitation in addition to somatic care to improve the QOL in this severely ill population.

Identifiants

pubmed: 36400586
pii: S0041-1345(22)00721-7
doi: 10.1016/j.transproceed.2022.10.051
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2598-2602

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

László Ablonczy (L)

Gottsegen National Cardiovascular Center, Pediatric Heart Center, Budapest, Hungary.

Zita Mayer (Z)

Gottsegen National Cardiovascular Center, Pediatric Heart Center, Budapest, Hungary.

Orsolya Somoskövi (O)

Gottsegen National Cardiovascular Center, Pediatric Heart Center, Budapest, Hungary.

Andrea Berkes (A)

Department of Pediatrics, University of Debrecen Clinical Center, Debrecen, Hungary.

Orsolya Csenteri (O)

Gottsegen National Cardiovascular Center, Pediatric Heart Center, Budapest, Hungary.

Eva Kis (E)

Gottsegen National Cardiovascular Center, Pediatric Heart Center, Budapest, Hungary. Electronic address: kiseva.mail@gmail.com.

György S Reusz (GS)

1st Department of Pediatrics, Semmelweis University, Budapest, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH